Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Asciminib |
Trade Name | Scemblix |
Synonyms | ABL001|ABL-001 |
Drug Descriptions |
Scemblix (asciminib) is an allosteric inhibitor of BCR-ABL that binds to a unique location outside the ATP binding site, resulting in decreased BCR-ABL kinase activity and reduced tumor growth (PMID: 31543464, PMID: 31826340). Scemblix (asciminib) is FDA approved for use in patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) after two or more tyrosine kinase inhibitor treatments, and in adult patients with Ph+ CML in CP harboring ABL1 T315I (FDA.gov). |
DrugClasses | BCR-ABL Inhibitor 29 |
CAS Registry Number | 1492952-76-7 |
NCIT ID | C114494 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Asciminib | Asciminib | 0 | 11 |
Asciminib + Dasatinib | Asciminib Dasatinib | 0 | 2 |
Asciminib + Dasatinib + Prednisone | Asciminib Dasatinib Prednisone | 0 | 1 |
Asciminib + Hydroxyurea + Ponatinib | Asciminib Hydroxyurea Ponatinib | 0 | 0 |
Asciminib + Imatinib | Asciminib Imatinib | 0 | 4 |
Asciminib + Nilotinib | Asciminib Nilotinib | 0 | 3 |
Asciminib + Ponatinib | Asciminib Ponatinib | 0 | 0 |